RespiraSense technology from PMD Device Solutions shows potential to predict 7-day mortality

STOCKHOLM, SWEDEN / ACCESSWIRE / September 17, 2024 / PMD Device Solutions (FRA:8T0)(STO:PMDS) PMD Device Solutions AB (ticker symbol: PMDS), a leading digital health technology company, today announced the results of a recent clinical study confirming the capabilities of its RespiraSense monitoring technology to predict 7-day mortality.

The study, which included 402 patients, showed that 4 hours of continuous respiratory rate monitoring with RespiraSense accurately predicted 7-day mortality (n=22). This sets a new standard for patient monitoring and intervention, especially in emergency care where it is critical to determine which patients need to be admitted and which can be safely discharged. The study was conducted between May 18, 2023 and January 31, 2024 in the Emergency Department and Outpatient Clinic of Kitovu Hospital in Masaka, Uganda.